Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world.
Data showed LOXO-305 was broadly effective in patients resistant to BTK inhibitors regardless of whether they harbored a putative mechanism of resistance to the widely used blood cancer drugs.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
AbbVie said Tuesday that the FDA had placed a partial clinical hold on all Venclexta studies in myeloma due to a higher rate of deaths in the Phase III BELLINI study.